CAREY STEPHEN P. sold $265K of ANIP

CAREY STEPHEN P. (SVP & CFO) sold 3,312 shares of ANI PHARMACEUTICALS INC (ANIP) at $80.00 ($0.26M total) on 2026-06-05 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · CAREY STEPHEN P.
Published Jun 9, 2026, 10:33 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jun 9, 2026, 10:35 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$ANIP
Neutral
high confidence
Mentioned
$ANIP
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$ANIPNeutralLow
01

Why it matters

Insider sales can influence sentiment, but 10b5-1 pre-arranged plans are generally less informative about near-term fundamentals.

02

Market read

Traders may note the scheduled insider selling, but there is no accompanying fundamental catalyst in the text.

03

What to watch

The article provides only the sale details; it does not indicate changes in operating outlook, financing needs, or new company-specific catalysts.

Relevance 3/10Novelty 5/10Timing: Filed June 9; sale executed June 5

Background

The article is an SEC EDGAR Form 4 insider transaction disclosure for ANI Pharmaceuticals, Inc.

Company-level read

Ticker impact

$ANIPNeutralHigh confidence
Context

SEC Form 4 shows ANIP CFO Stephen P. Carey sold 3,312 shares in an open-market transaction under a 10b5-1 plan.

Expected impact

Likely minimal near-term price impact; any effect would be sentiment-driven and short-lived.

Evidence & confidence

The filing is a Form 4 insider sale with explicit 10b5-1 pre-arrangement, which typically reduces interpretive weight versus discretionary selling.

Market effects

No sector read-across; this is company-specific insider transaction disclosure.

None indicated.

None indicated.

Counterpoint

Because the sale is under a 10b5-1 plan, it may reflect scheduled liquidity needs rather than bearish expectations.

Key entities

  • ANI Pharmaceuticals, Inc.

    Subject of the Form 4 insider transaction disclosure (ANIP).

  • Stephen P. Carey

    SVP & CFO who sold 3,312 shares on June 5 under a 10b5-1 plan.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$ANIPHighAI 9/10

ANI Pharmaceuticals Inc (ANIP) Q3 2026 Earnings Call Highlights: Strong Revenue Growth

ANI Pharmaceuticals (ANIP) reported Q3 2026 revenue of $290.8M (+28% YoY) and raised 2026 guidance. CEO Lalwani discussed a $560M cash offer for Aegidus Therapeutics, funded by cash and debt. Emcitate's U.S. pricing set at $74,026 per pack. Cortrophin demand exceeded expectations, causing temporary pharmacy bottlenecks. The company aims to expand prescriber base and identify more MCT8 deficiency patients.

$ANIPHighAI 8/10

ANI Pharma (ANIP) Q3 2026 Earnings Call Transcript

ANI Pharma (ANIP) reported Q3 2026 revenue of $290.8M, up 28% YoY, with adjusted EBITDA of $82.3M, up 40% YoY. Rare disease revenues grew 36% YoY, while generics grew 11%. The company revised Cortrophin Gel revenue guidance to $480M-$500M for 2026, down from $520M-$540M, citing supply chain issues. ANIP also announced an offer to acquire Aegidus Therapeutics, aiming to expand its rare disease portfolio.

$ANIPHighAI 8/10

ANI Pharmaceuticals Q3 Earnings Call Highlights

ANI Pharmaceuticals reported Q3 revenue of $104.5M, up 11% YoY. The company announced a $434M acquisition of Egetis, adding rare disease drug EMCITATE, expected to close in late 2026. ANI raised its 2026 revenue forecast to $1.085B-$1.125B and expects EMCITATE to generate over $300M in peak sales. The company has $420.8M in cash and $616.9M in debt.

$ANIPHigh

ANI Pharmaceuticals (NASDAQ:ANIP) reports strong Q3 2026

ANI Pharmaceuticals reported Q3 2026 revenue of $290.8M, beating estimates by 4.3% and growing 27.6% YoY. Adjusted EPS of $2.70 beat estimates by 23.8%. The company reconfirmed its revenue guidance of $1.11B and raised its adjusted EPS guidance to $9.54. EBITDA guidance was set at $295M, above consensus. Operating margin increased to 18% from 15.9% YoY.